Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases.
Bony metastases from prostate cancer are a significant cause of morbidity and mortality. These metastases are predominantly blastic (bone-forming) and commonly cause increased serum levels of parathyroid hormone (PTH) as calcium ions are transferred from serum into blastic bone. The epidemiologic and clinical significance of secondary hyperparathyroidism in advanced prostate cancer have not been widely appreciated. Prostate cancer bony metastases show increased expression of the PTH receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone. Thus, blastic metastases appear to induce a "vicious cycle" in which PTH resorbs normal bone to support the growth of blastic bone. Recognition of the potential role of PTH in the progression of skeletal metastases suggests novel opportunities for prostate cancer secondary prevention. In particular, we propose that suppressing serum PTH in advanced prostate cancer may reduce morbidity by decreasing fractures and pain caused by bone resorption and may reduce mortality by retarding the progression of metastatic disease.
Schwartz
Gary G
GG
Departments of Cancer Biology and Epidemiology and Prevention, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA. gschwart@wfubmc.edu
D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D018450:Disease Progression; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000503:physiopathology; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood*; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology* / Q000503:physiopathology
D010281:Parathyroid Hormone